CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5379.92M
Enterprise Value 3141.04M
Trailing P/E N/A
Forward P/E 1-3.27
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.61
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.55

Trading Information

Stock Price History

Beta (3Y Monthly) 1.38
52-Week Change 3-53.33%
S&P500 52-Week Change 30.90%
52 Week High 314.00
52 Week Low 34.82
50-Day Moving Average 36.18
200-Day Moving Average 310.00

Share Statistics

Avg Vol (3 month) 31.28M
Avg Vol (10 day) 3406.4k
Shares Outstanding 5N/A
Float 50.59M
% Held by Insiders 10.74%
% Held by Institutions 188.51%
Shares Short (Jul 31, 2019) 48.58M
Short Ratio (Jul 31, 2019) 413.13
Short % of Float (Jul 31, 2019) 412.56%
Short % of Shares Outstanding (Jul 31, 2019) 412.49%
Shares Short (prior month Jun 28, 2019) 48.43M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-24.27%
Return on Equity (ttm)-39.11%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-43.75M
EBITDA -91.22M
Net Income Avi to Common (ttm)-85.12M
Diluted EPS (ttm)-1.38
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)241.21M
Total Cash Per Share (mrq)3.51
Total Debt (mrq)2.33M
Total Debt/Equity (mrq)0.99
Current Ratio (mrq)16.20
Book Value Per Share (mrq)3.44

Cash Flow Statement

Operating Cash Flow (ttm)-82.32M
Levered Free Cash Flow (ttm)-55.39M